Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)

What this Trial Is About

Researchers are conducting a prospective, single-center observational study to understand how flow mediated dilatation (FMD) can predict outcomes in patients with acute coronary syndromes (ACS). This study also evaluates the use of a new method called Cor-IS technology alongside echocardiographic and biochemical measurements. The study focuses on patients hospitalized with ACS, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Participants will undergo assessments of their endothelial function using two methods: traditional flow mediated dilatation of the brachial artery and the novel Cor-IS technology. They will also receive transthoracic echocardiograms and have blood samples taken to measure plasma biomarkers. All evaluations are observational, meaning no treatments are assigned by the study. These procedures aim to monitor heart function and biochemical markers over time. During the study, researchers will track patient outcomes for 12 months, focusing on measures such as brachial artery function, major adverse cardiac events (MACE), rehospitalizations for angina, need for revascularization, and heart failure occurrences. Participants must be able to consent and follow the study’s schedule. This helps researchers gather comprehensive data on the predictive value of the tested methods in ACS. The total participation covers the initial hospitalization and follow-up assessments during the year after enrollment.

A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices